Last reviewed · How we verify
SaiLuoTong capsule
SaiLuoTong capsule is a Traditional Chinese medicine compound Small molecule drug developed by Shineway Pharmaceutical Co.,Ltd. It is currently in Phase 3 development for Angina pectoris. Also known as: The effects of SaiLuoTong capsule on VaD.
SaiLuoTong capsule is a traditional Chinese medicine compound that works by improving blood circulation and reducing inflammation.
SaiLuoTong capsule is a small molecule neurokinin 1 receptor antagonist, classified as an antagonist. It is being studied for various conditions including memory impairment, dementia, vascular, and vascular dementia in clinical trials.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | SaiLuoTong capsule |
|---|---|
| Also known as | The effects of SaiLuoTong capsule on VaD |
| Sponsor | Shineway Pharmaceutical Co.,Ltd |
| Drug class | Traditional Chinese medicine compound |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of SaiLuoTong capsule is not fully understood, but it is believed to involve the activation of certain cellular pathways that promote blood flow and reduce inflammation. This may be achieved through the modulation of various molecular targets, including nitric oxide synthase and cyclooxygenase-2.
Approved indications
- Angina pectoris
Common side effects
- Gastrointestinal upset
Key clinical trials
- The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule (PHASE3)
- CognivAiD Real-World Evidence Clinical Registry (CONNECT Registry)
- The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SaiLuoTong capsule CI brief — competitive landscape report
- SaiLuoTong capsule updates RSS · CI watch RSS
- Shineway Pharmaceutical Co.,Ltd portfolio CI
Frequently asked questions about SaiLuoTong capsule
What is SaiLuoTong capsule?
How does SaiLuoTong capsule work?
What is SaiLuoTong capsule used for?
Who makes SaiLuoTong capsule?
Is SaiLuoTong capsule also known as anything else?
What drug class is SaiLuoTong capsule in?
What development phase is SaiLuoTong capsule in?
What are the side effects of SaiLuoTong capsule?
Related
- Drug class: All Traditional Chinese medicine compound drugs
- Manufacturer: Shineway Pharmaceutical Co.,Ltd — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Angina pectoris
- Also known as: The effects of SaiLuoTong capsule on VaD
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing